又一家面值退市！多次“自救”无果，5年亏超32亿

Core Viewpoint - The company *ST Jiyao is facing delisting due to its stock price falling below 1 yuan for 20 consecutive trading days, triggering the Shenzhen Stock Exchange's delisting rules [1] Financial Performance - *ST Jiyao has reported continuous losses for five years, with a cumulative net profit loss exceeding 3.2 billion yuan from 2019 to 2023, and an additional loss of 231 million yuan in the first three quarters of 2024 [3] - By the end of 2024, the company's net assets are projected to be between -1.18 billion yuan and -830 million yuan, indicating financial delisting risks [3] - As of September 30, 2024, the company's debt ratio has risen to 161.77%, with a current ratio of only 0.16 [3] Company Background - The company was originally known as Tonghua Shuanglong Chemical Co., Ltd., primarily producing white carbon black for defense chemicals. It transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical, forming a dual business model of "chemicals + pharmaceuticals" [6] - After rebranding to Jiyao Holdings in 2017, the company aggressively pursued acquisitions, acquiring over ten companies within three years, covering eight major sectors including pharmaceutical manufacturing, commerce, and research [6] Goodwill and Impairment Issues - The company's aggressive cross-industry expansion has led to significant goodwill risks, with cumulative goodwill impairment exceeding 1.5 billion yuan from 2019 to 2024, directly contributing to net profit losses [7] - In 2019, the company reported revenue of 1.066 billion yuan but incurred a net profit loss of 1.772 billion yuan, with asset impairment accounting for over 70% of the total net profit loss [7] Failed Restructuring Attempts - *ST Jiyao has made multiple unsuccessful attempts at self-rescue through capital operations, including a failed transfer of control to the Jilin Provincial State-owned Assets Management Company in 2019 due to unresolved terms [8] - The company attempted to acquire Xiu Zheng Pharmaceutical, but the deal was terminated due to the significant revenue disparity, leading to a regulatory investigation and a fine of 600,000 yuan [8] - In November 2020, a proposed transfer of control to Bencao Hui Pharmaceutical fell through due to disputes, and a restructuring application in June 2023 was ultimately rejected by the court [9] Recent Developments - On March 19, 2025, *ST Jiyao's stock price first fell below 1 yuan, leading to a continued decline, culminating in the announcement of its delisting on April 23, 2025 [10] - Since the beginning of 2025, at least four other listed companies have also faced similar delisting conditions [10]